Aldehyde dehydrogenase 1A3 (ALDH1A3) promotes tumor growth, metastasis, and chemoresistance in multiple cancers, including triple-negative breast cancer (TNBC), yet no clinically approved, isoform-selective inhibitors exist. Here, ALDH1A3 is linked to triple-negative breast carcinoma.